Equillium Inc

Equillium Inc

  • Price (USD)5.20
  • Today's Change-0.08 / -1.52%
  • Shares traded253.14k
  • 1 Year change+12.80%
  • Beta--
Data delayed at least 15 minutes, as of Jan 15 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Equillium, Inc. is a biotechnology company. The Company develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. It plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.

  • Revenue in USD (TTM)0.00
  • Net income in USD-28.46m
  • Incorporated2017
  • Employees26.00
  • Location
    Equillium Inc2223 Avenida de La Playa Ste 105LA JOLLA 92037-3217United StatesUSA
  • Phone+1 (858) 412-5302
  • Fax+1 (302) 636-5454
  • Websitehttp://equilliumbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Orgenesis Inc14.43m-49.72m125.13m309.00--1.32--8.67-2.462.810.74543.920.15172.983.1546,708.74-53.12---78.55--67.22---350.27--7.68-27.490.1123----------380.20--
Aytu Bioscience Inc39.71m-13.00m125.29m75.00--1.00--3.16-2.27-2.275.537.240.4611.7110.16529,500.10-15.09-56.26-17.97-70.9472.3168.06-32.73-228.912.51-6.250.00--277.47153.9249.80------
Merion Inc220.94k-2.22m125.38m13.00------567.49-0.0125-0.01250.0012-0.03180.12851.957.8816,995.38-129.24-54.99-----36.5566.43-1,006.14-212.710.0791-12.29----377.00-23.3577.04------
Corbus Pharmaceuticals Holdings Inc5.85m-129.24m126.06m141.00--4.22--21.54-1.78-1.780.08080.35550.0714----41,507.45-157.64-109.15-280.90-162.46-----2,208.24-409.86---249.620.3793--649.51---28.35--111.73--
Genocea Biosciences Inc1.36m-38.09m126.51m59.00--6.25--93.09-1.27-1.270.03870.39190.0164----23,033.90-46.03-76.40-58.32-92.42-----2,802.43-23,815.14----0.4056-------40.05---5.67--
Celcuity Inc0.00-8.73m126.76m27.00--9.17-----0.851-0.8510.001.340.00----0.00-47.64---50.32--------------0.0011------1.62------
Galectin Therapeutics Inc0.00-20.89m127.28m7.00--4.34-----0.3976-0.39760.000.55290.00----0.00-48.93-89.89-51.17-103.57------------0.00-------34.11------
X4 Pharmaceuticals Inc3.00m-54.57m128.50m58.00--1.43--42.83-2.84-2.840.15665.510.0247--2.5451,724.14-44.97---49.34-------1,818.93-----27.380.2216---100.00---24.12------
Adamas Pharmaceuticals Inc69.80m-62.21m130.05m136.00------1.86-2.22-2.222.48-1.210.44570.314510.59513,227.90-39.72-51.24-48.71-56.7097.30---89.12-476.923.72-3.621.36--60.48-0.436819.70---57.41--
Equillium Inc0.00-28.46m130.56m26.00--1.67-----1.56-1.560.003.160.00----0.00-36.64---39.00-------------75.960.1122-------93.20------
Leap Therapeutics Inc1.13m-38.87m131.84m24.00--2.48--117.19-1.09-1.090.02440.89070.0301--2.3446,875.00-77.12-224.03-95.94-------2,560.00------0.00-------43.74------
Liquidia Corp0.00-58.17m132.07m64.00--1.76-----2.12-
LifeVantage Corp231.51m12.24m132.16m247.0011.093.878.470.57090.83690.836915.812.403.672.58103.70937,303.6019.3913.4531.0327.6783.5183.325.293.171.1932.000.00--3.084.1255.4610.1418.26--
Vivakor inc1.02m-761.92k134.07m25.00--10.38--131.01-0.0028-0.00280.00360.0938-----------5.01---8.013.7586.24-124.57-435.831.21-49.500.1766---100.00--0.8773------
Data as of Jan 15 2021. Currency figures normalised to Equillium Inc's reporting currency: US Dollar USD

Institutional shareholders

25.46%Per cent of shares held by top holders
HolderShares% Held
Victory Capital Management, Inc. (Investment Management)as of 30 Sep 20202.35m9.52%
RTW Investments LPas of 30 Sep 20201.00m4.06%
Franklin Advisers, Inc.as of 30 Sep 2020700.00k2.83%
Farallon Capital Management LLCas of 30 Sep 2020700.00k2.83%
The Vanguard Group, Inc.as of 30 Sep 2020666.04k2.69%
Arctic Fund Management AS (Sweden)as of 30 Nov 2020225.00k0.91%
Fidelity Management & Research Co. LLCas of 30 Sep 2020209.80k0.85%
Alyeska Investment Group LPas of 30 Sep 2020153.09k0.62%
Asymmetry Capital Management LPas of 30 Sep 2020143.54k0.58%
Invesco Capital Management LLCas of 30 Sep 2020138.61k0.56%
More ▼
Data from 30 Sep 2020 - 30 Nov 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.